Abstract
We performed a win ratio (WR) analysis of REPRIEVE, a randomized trial of pitavastatin vs placebo for CVD in people with HIV, to assess robustness to event severity. WR aligns with primary findings, and provides insight into pitavastatin protections: persistent advantage over placebo on CV Death, Stroke, and Myocardial Infarction.